Advances in Mechanism of Coexistence and
Pharmaceutical Treatment of Chronic Heart Failure and Depression

doi:10.12114/j.issn.1007-9572.2021.01.034

Abstract

Abstract:

The coprevalence of chronic heart failure (CHF) and depression is 10%-79%, the pathogenesis of these two diseases is related to the activation of immune inflammatory system, insulin resistance and intestinal flora imbalance, and relevant regulation is bidirectional and complex. There is a lack of efficient drugs for both CHF and depression recommended by available diagnosis and treatment guidelines and present clinical practice. But it has recently been reported that some drugs (sacubitril/valsartan, new antidepressants, shensongyangxin and qiliqiangxin capsules, regulators of the intestinal flora) may be partially effective for CHF with depression.We reviewed the mechanism of coexistence and pharmaceutical treatment of CHF and depression, providing new ideas and evidence for clinical diagnosis and treatment of CHF and depression.

Key words: Heart failure, Depressive disorder, Comorbidity, Multiple chronic conditions, Drug therapy, Review

摘要：

慢性心力衰竭（CHF）和抑郁症的共病率为10%~79%，二者的发病机制均涉及免疫炎症系统激活、胰岛素抵抗、肠道菌群失调等方面，而其机制的调节亦是双向的、复杂的。现有的诊疗指南及临床实践中尚缺乏对二者同时有效的药物，但有近期报道部分药物如沙库巴曲缬沙坦、新型抗抑郁药、参松养心胶囊和芪苈强心胶囊、肠道菌群调节剂等对二者均有一定的治疗作用。本文将对二者的共同发病机制及药物治疗的研究进展进行综述，为CHF和抑郁症共病的临床诊断及治疗提供新的思路和依据。

关键词: 心力衰竭, 抑郁症, 共病现象, 慢性病共病, 药物疗法, 综述

CLC Number:

R541.62R749.41

YANG Rongjun, SHI Yufang, WANG Qinghai.

Advances in Mechanism of Coexistence and Pharmaceutical Treatment of Chronic Heart Failure and Depression [J]. Chinese General Practice, 2022, 25(05): 625-630.

杨荣军,史钰芳,王庆海. 慢性心力衰竭与抑郁症共同发病机制及药物治疗的研究进展[J]. 中国全科医学, 2022, 25(05): 625-630. DOI: 10.12114/j.issn.1007-9572.2021.01.034.

References 63

[1]	MA L Y, CHEN W W, GAO R L，et al. China cardiovascular diseases report 2018: an updated summary[J]. J Geriatr Cardiol，2020，17(1):1-8. DOI：10.11909/j.issn.1671-5411.2020.01.001.
[2]	SOKORELI I, DE VRIES J J G, PAUWS S C，et al. Depression and anxiety as predictors of mortality among heart failure patients：systematic review and meta-analysis[J]. Heart Fail Rev，2016，21(1):49-63. DOI：10.1007/s10741-015-9517-4.
[3]	RUSTAD J K, STERN T A, HEBERT K A，et al. Diagnosis and treatment of depression in patients with congestive heart failure：a review of the literature[J]. Prim Care Companion CNS Disord，2013，15(4):PCC.13r01511. DOI：10.4088/PCC.13r01511.
[4]	CELIK E, CAY S, SENSOY B，et al. Heart failure functional class associated with depression severity but not anxiety severity[J]. Acta Cardiol Sin，2016，32(1):55-61.
[5]	YU H W, DONG Y Y, DANG Y H. The modulatory activity of T cell immunoglobulin and mucin domain-containing protein 3 on T lymphocytes in patients with chronic heart failure[J]. Zhonghua Yi Xue Za Zhi，2020，100(17):1315-1319. DOI：10.3760/cma.j.cn112137-20190823-01876.
[6]	SEGIET O A, PIECUCH A, MIELANCZYK L，et al. Role of interleukins in heart failure with reduced ejection fraction[J]. Anatol J Cardiol，2019，22(6):287-299. DOI：10.14744/AnatolJCardiol.2019.32748.
[7]	KOWALCZYK M, SZEMRAJ J, BLIZNIEWSKA K，et al. An immune gate of depression - Early neuroimmune development in the formation of the underlying depressive disorder[J]. Pharmacol Rep，2019，71(6):1299-1307. DOI：10.1016/j.pharep.2019.05.022.
[8]	DICKENS C. Depression in people with coronary heart disease：prognostic significance and mechanisms[J]. Curr Cardiol Rep，2015，17(10):1-10. DOI：10.1007/s11886-015-0640-6.
[9]	MAO R Z, ZHANG C, CHEN J，et al. Different levels of pro- and anti-inflammatory cytokines in patients with unipolar and bipolar depression[J]. J Affect Disord，2018，237(9):65-72.
[10]	MILLER A H, RAISON C L. The role of inflammation in depression：from evolutionary imperative to modern treatment target[J]. Nat Rev Immunol，2016，16(1):22-34.
[11]	SU J, WANG J H, MA Y Y，et al. Inflammation associated with chronic heart failure leads to enhanced susceptibility to depression[J]. FEBS J，2019，286(14):2769-2786. DOI：10.1111/febs.14839.
[12]	ZHANG H F, ZHANG X, GAO F. Insulin and cardiovascular protection：from bench to bedside[J]. Acta Physiol Sin，2018，70(1):61-70.
[13]	ZHENG L L, LI B B, LIN S H，et al. Role and mechanism of cardiac insulin resistance in occurrence of heart failure caused by myocardial hypertrophy[J]. Aging （Albany NY），2019，11(16):6584-6590. DOI：10.18632/aging.102212.
[14]	HAMER J A, TESTANI D, MANSUR R B，et al. Brain insulin resistance：a treatment target for cognitive impairment and anhedonia in depression[J]. Exp Neurol，2019，315:1-8.
[15]	ZOU X H, SUN L H, YANG W，et al. Potential role of insulin on the pathogenesis of depression[J]. Cell Prolif，2020，53(5):E12806-12819. DOI：10.1111/cpr.12806.
[16]	SOTO M, HERZOG C, PACHECO J A，et al. Gut microbiota modulate neurobehavior through changes in brain insulin sensitivity and metabolism[J]. Mol Psychiatry，2018，23(12):2287-2301. DOI：10.1038/s41380-018-0086-5.
[17]	JIA Q J, LI H, ZHOU H，et al. Role and effective therapeutic target of gut microbiota in heart failure[J]. Cardiovasc Ther，2019，2019(11):5164298-5164309.
[18]	CHEN X, LI H Y, HU X M，et al. Current understanding of gut microbiota alterations and related therapeutic intervention strategies in heart failure[J]. Chin Med J （Engl），2019，132(15):1843-1855. DOI：10.1097/CM9.0000000000000330.
[19]	SATA Y, MARQUES F Z, KAYE D M. The emerging role of gut dysbiosis in cardio-metabolic risk factors for heart failure[J]. Curr Hypertens Rep，2020，22(5):38-46. DOI：10.1007/s11906-020-01046-0.
[20]	LIU R T, WALSH R F L, SHEEHAN A E. Prebiotics and probiotics for depression and anxiety：a systematic review and meta-analysis of controlled clinical trials[J]. Neurosci Biobehav Rev，2019，102:13-23. DOI：10.1016/j.neubiorev.2019.03.023.
[21]	LIANG S, WU X L, HU X，et al. Recognizing depression from the Microbiota-Gut-Brain axis[J]. Int J Mol Sci，2018，19(6):E1592. DOI：10.3390/ijms19061592.
[22]	AMADIO P, ZARÀ M, SANDRINI L，et al. Depression and cardiovascular disease：the viewpoint of platelets[J]. Int J Mol Sci，2020，21(20):E7560. DOI：10.3390/ijms21207560.
[23]	WILLIAMS M S, ZIEGELSTEIN R C, MCCANN U D，et al. Platelet serotonin signaling in patients with cardiovascular disease and comorbid depression[J]. Psychosom Med，2019，81(4):352-362. DOI：10.1097/PSY.0000000000000689.
[24]	SAMA J, VAIDYA D, MUKHERJEE M，et al. Effects of clinical depression on left ventricular dysfunction in patients with acute coronary syndrome[J]. J Thromb Thrombolysis，2021，51(3):693-700. DOI：10.1007/s11239-020-02268-4.
[25]	SELIM A M, SARSWAT N, KELESIDIS I，et al. Plasma serotonin in heart failure：possible marker and potential treatment target[J]. Heart Lung Circ，2017，26(5):442-449.
[26]	LIU M Y, ZHANG L J. Role of Ginkgo biloba extract in regulating 5-hydroxytrytamine and its receptor in heart failure mice[J]. Zhonghua Yi Xue Za Zhi，2018，98(25):2024-2029.
[27]	曹娟，刘习建，龚婷，等. 冠心病与抑郁症共病机制及治疗的研究进展[J]. 生命的化学，2019，39(5):993-997. DOI：10.13488/j.smhx.20190009.
[28]	MAVRIDES N, NEMEROFF C B. Treatment of affective disorders in cardiac disease[J]. Dialogues Clin Neurosci，2015，17(2):127-140. DOI：10.31887/DCNS.2015.17.2/nmavrides.
[29]	KIM Y K, NA K S, MYINT A M，et al. The role of pro-inflammatory cytokines in neuroinflammation，neurogenesis and the neuroendocrine system in major depression[J]. Prog Neuropsychopharmacol Biol Psychiatry，2016，64:277-284.
[30]	BROWN L, KARMAKAR C, GRAY R，et al. Heart rate variability alterations in late life depression：a meta-analysis[J]. J Affect Disord，2018，235(1):456-466. DOI：10.1016/j.jad.2018.04.071.
[31]	SESSA F, ANNA V, MESSINA G，et al. Heart rate variability as predictive factor for sudden cardiac death[J]. Aging：Albany NY，2018，10(2):166-177. DOI：10.18632/aging.101386.
[32]	HARTMANN R, SCHMIDT F M, SANDER C，et al. Heart rate variability as indicator of clinical state in depression[J]. Front Psychiatry，2018，9(2):735-743.
[33]	BORRIONE L, BRUNONI A R, SAMPAIO-JUNIOR B，et al. Associations between symptoms of depression and heart rate variability：an exploratory study[J]. Psychiatry Res，2018，262(4):482-487. DOI：10.1016/j.psychres.2017.09.028.
[34]	KIRCANSKI K, WILLIAMS L M, GOTLIB I H. Heart rate variability as a biomarker of anxious depression response to antidepressant medication[J]. Depress Anxiety，2019，36(1):63-71. DOI：10.1002/da.22843.
[35]	CHOI K W, JEON H J. Heart rate variability for the prediction of treatment response in major depressive disorder[J]. Front Psychiatry，2020，11:607. DOI：10.3389/fpsyt.2020.00607.
[36]	KOCH C, WILHELM M, SALZMANN S，et al. A meta-analysis of heart rate variability in major depression[J]. Psychol Med，2019，49(12):1948-1957.
[37]	SCHERF-CLAVEL M, WURST C, NITSCHKE F，et al. Extent of cortisol suppression at baseline predicts improvement in HPA axis function during antidepressant treatment[J]. Psychoneuroendocrinology，2020，114(4):104590-104598.
[38]	DWYER J B, AFTAB A, RADHAKRISHNAN R，et al. Hormonal treatments for major depressive disorder：state of the art[J]. Am J Psychiatry，2020，177(8):686-705. DOI：10.1176/appi.ajp.2020.19080848.
[39]	REINDL M, FEISTRITZER H J, REINSTADLER S J，et al. Thyroid-stimulating hormone and adverse left ventricular remodeling following ST-segment elevation myocardial infarction[J]. Eur Heart J Acute Cardiovasc Care，2019，8(8):717-726.
[40]	FLORIANI C, GENCER B, COLLET T H，et al. Subclinical thyroid dysfunction and cardiovascular diseases：2016 update[J]. Eur Heart J，2018，39(7):503-507.
[41]	LOH H H, LIM L L, YEE A，et al. Association between subclinical hypothyroidism and depression：an updated systematic review and meta-analysis[J]. BMC Psychiatry，2019，19(1):12-22. DOI：10.1186/s12888-018-2006-2.
[42]	YANG G D, WANG Y, MA A Q，et al. Subclinical thyroid dysfunction is associated with adverse prognosis in heart failure patients with reduced ejection fraction[J]. BMC Cardiovasc Disord，2019，19(1):83-94.
[43]	WILDISEN L, MOUTZOURI E, BEGLINGER S，et al. Subclinical thyroid dysfunction and depressive symptoms：protocol for a systematic review and individual participant data meta-analysis of prospective cohort studies[J]. BMJ Open，2019，9(7):e029716. DOI：10.1136/bmjopen-2019-029716.
[44]	FISCHER S, EHLERT U, AMIEL CASTRO R. Hormones of the hypothalamic-pituitary-gonadal （HPG） axis in male depressive disorders - a systematic review and meta-analysis[J]. Front Neuroendocrinol，2019，55(10):100792-100801.
[45]	GRANDE D, TERLIZZESE P, GIOIA M I，et al. New frontiers in the therapeutic approach of patients with cardiovascular and endocrine diseases[J]. Endocr Metab Immune Disord Drug Targets，2019，19(5):605-621.
[46]	ALEM M M. Endothelial dysfunction in chronic heart failure：assessment，findings，significance，and potential therapeutic targets[J]. Int J Mol Sci，2019，20(13):3198-3215. DOI：10.3390/ijms20133198.
[47]	ZUCHI C, TRITTO I, CARLUCCIO E，et al. Role of endothelial dysfunction in heart failure[J]. Heart Fail Rev，2020，25(1):21-30. DOI：10.1007/s10741-019-09881-3.
[48]	KOKRAS N, PAPADOPOULOU E, GEORGIOPOULOS G，et al. The effect of treatment response on endothelial function and arterial stiffness in depression. A prospective study[J]. J Affect Disord，2019，252(6):190-200. DOI：10.1016/j.jad.2019.04.024.
[49]	GREANEY J L, SAUNDERS E F H, SANTHANAM L，et al. Oxidative stress contributes to microvascular endothelial dysfunction in men and women with major depressive disorder[J]. Circ Res，2019，124(4):564-574. DOI：10.1161/CIRCRESAHA.118.313764.
[50]	HAN K M, CHOI S, KIM A，et al. The effects of 5-HTTLPR and BDNF Val66Met polymorphisms on neurostructural changes in major depressive disorder[J]. Psychiatry Res Neuroimaging，2018，273(3):25-34. DOI：10.1016/j.pscychresns.2018.01.005.
[51]	OZ M D, BASKAK B, UCKUN Z，et al. Association between serotonin 2A receptor （HTR2A），serotonin transporter （SLC6A4） and brain-derived neurotrophic factor （BDNF） gene polymorphisms and citalopram/sertraline induced sexual dysfunction in MDD patients[J]. Pharmacogenomics J，2020，20(3):443-450. DOI：10.1038/s41397-019-0127-8.
[52]	SOUSA A C, REIS R P D, PEREIRA A，et al. The genetic variant C825T of the beta 3 subunit of G protein is associated with hypertension in a Portuguese population[J]. Rev Port Cardiol （Engl Ed），2018，37(6):499-507. DOI：10.1016/j.repc.2017.09.018.
[53]	NAM Y J, CHO C H, KIM L，et al. Association of G-protein β3 subunit C825T polymorphism with seasonal variations in mood and behavior[J]. Psychiatry Investig，2018，15(2):200-204.
[54]	SONG E K, WU J R, MOSER D K，et al. Vitamin D supplements reduce depressive symptoms and cardiac events in heart failure patients with moderate to severe depressive symptoms[J]. Eur J Cardiovasc Nurs，2018，17(3):207-216.
[55]	DJOUSSÉ L, COOK N R, KIM E，et al. Supplementation with vitamin D and Omega-3 fatty acids and incidence of heart failure hospitalization：VITAL-heart failure[J]. Circulation，2020，141(9):784-786. DOI：10.1161/CIRCULATIONAHA.119.044645.
[56]	ZHAO Q, LI J F, YANG J，et al. Association of total cholesterol and HDL-C levels and outcome in coronary heart disease patients with heart failure[J]. Medicine （Baltimore），2017，96(9):e6094. DOI：10.1097/MD.0000000000006094.
[57]	POPOVIC B, ZANNAD F, LOUIS H，et al. Endothelial-driven increase in plasma thrombin generation characterising a new hypercoagulable phenotype in acute heart failure[J]. Int J Cardiol，2019，274(1):195-201.
[58]	GEISER F, MEIER C, WEGENER I，et al. Association between anxiety and factors of coagulation and fibrinolysis[J]. Psychother Psychosom，2008，77(6):377-383.
[59]	DERELI S, KILINÇEL O, ÇERIK I B，et al. Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction[J]. Acta Cardiol，2020，75(8):774-782. DOI：10.1080/00015385.2020.1730577.
[60]	CACCIATORE F, AMARELLI C, MAIELLO C，et al. Effect of Sacubitril-Valsartan in reducing depression in patients with advanced heart failure[J]. J Affect Disord，2020，272(4):132-137. DOI：10.1016/j.jad.2020.03.158.
[61]	LI X L, ZHANG J, HUANG J，et al. A multicenter，randomized，double-blind，parallel-group，placebo-controlled study of the effects of qili Qiangxin capsules in patients with chronic heart failure[J]. J Am Coll Cardiol，2013，62(12):1065-1072.
[62]	WANG X, HU D, DANG S，et al. Effects of traditional Chinese medicine shensong Yangxin capsules on heart rhythm and function in congestive heart failure patients with frequent ventricular premature complexes：a randomized，double-blind，multicenter clinical trial[J]. Chin Med J （Engl），2017，130(14):1639-1647.
[63]	刘岱岳，郭文勇，范鲁，等. 探讨人类肠道菌群调节剂联合抗抑郁药物治疗抑郁症的临床疗效[J]. 中国医学工程，2019，27(11):1-6. DOI：10.19338/j.issn.1672-2019.2019.11.001.

Advances in Mechanism of Coexistence and Pharmaceutical Treatment of Chronic Heart Failure and Depression

慢性心力衰竭与抑郁症共同发病机制及药物治疗的研究进展

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 63

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	TIAN Chen, LIU Jianing, TIAN Jinhui, GE Long. Living Systematic Reviews: Methods and Processes for Development [J]. Chinese General Practice, 2025, 28(30): 3853-3860.
[2]	WANG Tingting, TANG Yong, ZHANG Wenke, LI Zhigang. Research Progress on Exercise Intervention of Hyperuricemia [J]. Chinese General Practice, 2025, 28(30): 3841-3846.
[3]	MA Shuangshuang, XING Yanjiang, ZHANG Jiawei, WANG Jing. Research Progress on Cardiac Energy Metabolic Changes in Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2025, 28(30): 3831-3840.
[4]	XU Baichuan, WANG Yan, ZHANG Peng, LI Yiting, LIU Feilai, XIE Yang. Research and Analysis of Screening Tools for Chronic Obstructive Pulmonary Disease Comorbidity Lung Cancer [J]. Chinese General Practice, 2025, 28(30): 3847-3852.
[5]	ZHANG Peng, LIU Lidi, ZHANG Ying, YANG Ziyu, LIU Changming, TANG Yijun, LIAO Xiaoyang, JIA Yu. Interpretation and Clinical Implications of the 2024 Italian Guidelines for the Management of Adult Individuals with Overweight and Obesity and Metabolic Comorbidities That are Resistant to Behavioral Treatment [J]. Chinese General Practice, 2025, 28(30): 3747-3752.
[6]	ZHOU Sheng, DENG Changsheng, ZOU Guanyang, SONG Jianping. Research Progress on the Pathogenesis of Complications of Malaria in Cardiovascular Diseases [J]. Chinese General Practice, 2025, 28(27): 3466-3472.
[7]	LIU Zhenyu, WEI Yunpeng, WANG Jiangmin, XING Yan. Causal Association Study between Sleep Duration and Heart Failure [J]. Chinese General Practice, 2025, 28(27): 3441-3446.
[8]	HUANG Yulin, WANG Haoyun, LI Yanmei, XIAO Xueying. Symptom Clusters in Gastric Cancer Patients Receiving Chemotherapy: a Scoping Review [J]. Chinese General Practice, 2025, 28(26): 3338-3344.
[9]	LIU Wenjie, SUN Huang, LUO Wei, CHEN Xuan, PENG Yunzhu, LI Ruijie, MA Mier. Wearable Acoustic-electrocardiographic Remote Monitoring Device for Heart Failure [J]. Chinese General Practice, 2025, 28(25): 3104-3109.
[10]	YANG Chen, CHEN Tong, ZHANG Lifang, ZHANG Hongxu, LI Pengfei, ZHANG Xuejuan. Prognostic Impact of Dapagliflozin in Elderly Breast Cancer Survivors with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(24): 3053-3058.
[11]	HAN Bing, DU Shuzhen, MENG Xiaoxue, ZHANG Lu, CHEN Zixian, TENG Fengling. Plasma Periostin Levels Correlated with Myocardial Fibrosis in Patients with Heart Failure with Different Ejection Fraction [J]. Chinese General Practice, 2025, 28(24): 2979-2984.
[12]	LIU Yinyin, SUI Hongping, LI Tingting, JIANG Tongtong, SHI Tieying, XIA Yunlong. Advances in Risk Prediction Models for Cardiotoxicity Associated with Breast Cancer Treatment [J]. Chinese General Practice, 2025, 28(24): 3072-3078.
[13]	LI Miaoxiu, ZHU Bowen, KONG Lingjun, FANG Min. Progress in Research on Clinical Assessment Tools for Conservative Treatment of Adolescent Idiopathic Scoliosis [J]. Chinese General Practice, 2025, 28(24): 3079-3088.
[14]	XIAO Yao, WAN Jun. Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants [J]. Chinese General Practice, 2025, 28(24): 3066-3071.
[15]	RUAN Wanbai, LI Junfeng, YIN Yanmei, PENG Lei, ZHU Kexiang. Research Progress of Targeted Therapy and Immunotherapy for Pancreatic Cancer [J]. Chinese General Practice, 2025, 28(23): 2950-2960.